# Microwave technologies for biomedical diagnosis and therapy: advances, challenges, and perspectives

**Authors:** Sebastian Montoya-Villada, Erick Reyes-Vera, Jahir Orozco

PMC · DOI: 10.1007/s00604-025-07826-2 · Mikrochimica Acta · 2026-03-04

## TL;DR

Microwave technologies are being explored for biomedical uses like diagnosis and therapy due to their safety and sensitivity, though challenges remain in making them widely applicable.

## Contribution

This review integrates biophysical foundations with recent advances in microwave biosensing, imaging, and therapy, highlighting novel trends like AI and wearable platforms.

## Key findings

- Microwave systems offer non-ionizing, sensitive methods for detecting biomarkers and assessing tissues.
- Emerging trends like AI-driven interpretation and microfluidics are enhancing microwave sensing and therapy capabilities.
- Current barriers include dielectric model variability and limited in vivo validation, which hinder clinical translation.

## Abstract

Microwave technologies have emerged as powerful tools for biomedical diagnosis and therapy due to their non-ionizing nature, sensitivity to dielectric changes, and compatibility with compact, low-cost systems. This review provides a unified perspective that integrates the biophysical foundations of dielectric characterization with advances in biosensing, imaging, and therapeutic microwave platforms. A systematic examination of the primary material characterization techniques—non-resonant, transmission-line resonant, and metamaterial-based methods—highlights how their frequency-dependent interactions with biological media underpin molecular, cellular, and tissue-level sensing. We synthesize recent progress in microstrip and resonant biosensors for detecting biochemical, metabolic, oncological, and pathogenic biomarkers, alongside developments in microwave imaging for functional tissue assessment and energy-based therapies such as hyperthermia and ablation. This integrated framework clarifies how the methodological diversity of microwave systems supports increasingly specialized biomedical applications. Despite their promise, current microwave technologies face several barriers to clinical translation, including variability in dielectric models, calibration and reproducibility challenges, spatial-resolution constraints, and limited in vivo validation. Addressing these limitations requires advancing beyond traditional architectures. Accordingly, this review also consolidates emerging trends in microfluidics, wearable and implantable platforms, artificial intelligence (AI)-driven signal interpretation, and multimodal integration, illustrating how these capabilities enhance sensing performance, enable adaptive therapy monitoring, and advance microwave systems toward personalized theranostic applications. By articulating the interplay between methods, capabilities, and unresolved challenges, a comprehensive and timely roadmap is offered that distinguishes microwave technologies from conventional diagnostic modalities and underscores their unique potential in next-generation biomedical engineering.

## Full-text entities

- **Genes:** KDR (kinase insert domain receptor) [NCBI Gene 3791] {aka CD309, FLK1, VEGFR, VEGFR2}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, SPATA2 (spermatogenesis associated 2) [NCBI Gene 9825] {aka PD1, PPP1R145, tamo}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, PSG2 (pregnancy specific beta-1-glycoprotein 2) [NCBI Gene 5670] {aka CEA, PSBG2, PSG1}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, SRR (serine racemase) [NCBI Gene 63826] {aka ILV1, ISO1}
- **Diseases:** breast lesions (MESH:D061325), mitochondrial dysfunction (MESH:D028361), apnea (MESH:D001049), Parkinson's disease (MESH:D010300), visceral and muscle tumors (MESH:D019042), conditions (MESH:D020763), inflammation (MESH:D007249), Neurodegenerative disorders (MESH:D019636), amyotrophic lateral sclerosis (MESH:D000690), colorectal metastases (MESH:D009362), epilepsy (MESH:D004827), Melanomas (MESH:D008545), atrophy (MESH:D001284), atrophic (MESH:D020966), edema (MESH:D004487), chronic kidney disease (MESH:D051436), lung cancer (MESH:D008175), cardiovascular problems (MESH:D002318), AD (MESH:D000544), brain atrophy (MESH:C566985), adenocarcinoma (MESH:D000230), cancers (MESH:D009369), loss of neuronal function (MESH:D006315), diabetes (MESH:D003920), lung (MESH:D008171), ischemic lesions (MESH:D017202), noncommunicable diseases (MESH:D000073296), stroke (MESH:D020521), intracranial hemorrhages (MESH:D020300), respiratory (MESH:D012131), type 2 diabetes (MESH:D003924), apnea-hypopnea (MESH:D020181), bleeding (MESH:D006470), breast cancer (MESH:D001943), depression (MESH:D003866), chronic pain (MESH:D059350), melanoma skin cancer (MESH:D012878), renal damage (MESH:D007674), dengue (MESH:D003715), tissue (MESH:D017695), squamous cell carcinoma (MESH:D002294), Cognitive Impairment (MESH:D003072), glioblastoma (MESH:D005909), IoMT (MESH:C000719207), liver tumor (MESH:D008113), infectious disease (MESH:D003141), chronic diseases (MESH:D002908), brain tumor (MESH:D001932), burns (MESH:D002056), Metabolic and inflammatory diseases (MESH:D008659), hepatocellular carcinoma (MESH:D006528), Bacterial and fungal infections (MESH:D009181), necrosis (MESH:D009336), cerebral abnormalities (MESH:D014402), oncological (MESH:D000072716), basal cell carcinoma (MESH:D002280), hypopnea (MESH:D012891), Hyperthermia (MESH:D005334)
- **Chemicals:** salt (MESH:D012492), SiO2 (MESH:D012822), tacrolimus (MESH:D016559), sodium (MESH:D012964), AQ8111593092980 (-), graphene (MESH:D006108), Au (MESH:D006046), methanol (MESH:D000432), GaAs (MESH:C043055), polymer (MESH:D011108), acetone (MESH:D000096), serpentine (MESH:C009244), DTSP (MESH:C011240), lactate (MESH:D019344), cortisol (MESH:D006854), urea (MESH:D014508), Fe (MESH:D007501), Antimycin A (MESH:D000968), camrelizumab (MESH:C000631724), water (MESH:D014867), polystyrene (MESH:D011137), Glucose (MESH:D005947), FCCP (MESH:D002259), blood glucose (MESH:D001786), polydopamine (MESH:C568283), silicone (MESH:D012828), apatinib (MESH:C553458), hydrogen (MESH:D006859), MXene (MESH:C000723374)
- **Species:** Bacillus cereus (species) [taxon 1396], Escherichia coli (E. coli, species) [taxon 562], Lacticaseibacillus rhamnosus (species) [taxon 47715], Aspergillus niger (species) [taxon 5061], Homo sapiens (human, species) [taxon 9606], Saccharomyces cerevisiae (baker's yeast, species) [taxon 4932], Bacteria Latreille et al. 1825 (Bacteria stick insect, genus) [taxon 629395], Bos taurus (bovine, species) [taxon 9913], Severe acute respiratory syndrome coronavirus 2 (no rank) [taxon 2697049], Sus scrofa (pig, species) [taxon 9823]
- **Cell lines:** HepG2 — Homo sapiens (Human), Hepatoblastoma, Cancer cell line (CVCL_0027), HEC-1-A — Homo sapiens (Human), Type II endometrial adenocarcinoma, Cancer cell line (CVCL_0293), A549 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_0023)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12960498/full.md

## Figures

16 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12960498/full.md

## References

6 references — full list in the complete paper: https://tomesphere.com/paper/PMC12960498/full.md

---
Source: https://tomesphere.com/paper/PMC12960498